TELA Bio (TELA) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free TELA Stock Alerts $5.74 -0.11 (-1.88%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | marketbeat.comTELA Bio, Inc. (NASDAQ:TELA) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. decreased its stake in shares of TELA Bio, Inc. (NASDAQ:TELA - Free Report) by 76.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,736 shares of the company's stock after sMay 21, 2024 | finanznachrichten.deTELA Bio, Inc.: TELA Bio Appoints Greg Firestone as Chief Commercial OfficerMay 20, 2024 | globenewswire.comTELA Bio Appoints Greg Firestone as Chief Commercial OfficerMay 13, 2024 | marketbeat.comTELA Bio, Inc. (NASDAQ:TELA) Sees Large Increase in Short InterestTELA Bio, Inc. (NASDAQ:TELA - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 1,130,000 shares, an increase of 22.0% from the April 15th total of 926,000 shares. Based on an average daily volume of 149,700 shares, the days-to-cover ratio is presently 7.5 days.May 13, 2024 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call TranscriptMay 12, 2024 | investing.comTELA Bio stock target cut, keeps overweight rating on first quarter resultsMay 12, 2024 | msn.comTELA Bio Reports Strong First Quarter Growth, Expands Product PortfolioMay 12, 2024 | msn.comTELA Bio Awards Stock Units to New Employees as Hiring InducementMay 11, 2024 | finance.yahoo.comTELA Bio First Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)May 11, 2024 | finance.yahoo.comTELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued GrowthMay 11, 2024 | markets.businessinsider.comTELA Bio’s Robust Growth and Promising Outlook Merit Bullish StanceMay 10, 2024 | marketbeat.comTELA Bio (NASDAQ:TELA) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPSTELA Bio (NASDAQ:TELA - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.25. TELA Bio had a negative return on equity of 201.62% and a negative net margin of 79.83%. The firm had revenue of $16.60 million during the quarter, compared to analyst estimates of $15.90 million. During the same period last year, the company earned ($0.63) earnings per share.May 10, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comPiper Sandler Reaffirms Overweight Rating for TELA Bio (NASDAQ:TELA)Piper Sandler reaffirmed an "overweight" rating and set a $10.00 price target (down from $12.00) on shares of TELA Bio in a report on Friday.May 9, 2024 | globenewswire.comTELA Bio Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on TELA Bio (TELA)May 3, 2024 | msn.comScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reportsApril 25, 2024 | globenewswire.comTELA Bio to Announce First Quarter 2024 Financial ResultsApril 17, 2024 | msn.comTELA Bio Launches Innovative Hernia Repair Device in the U.S. MarketApril 16, 2024 | msn.comTELA Bio launches OviTex IHR for inguinal hernia repair in USApril 15, 2024 | globenewswire.comTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia ProceduresApril 11, 2024 | finance.yahoo.comMDXG: Legal AvenuesApril 10, 2024 | msn.comTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical AffairsApril 8, 2024 | finanznachrichten.deTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyApril 8, 2024 | globenewswire.comTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon StrategyMarch 25, 2024 | msn.comTELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024March 24, 2024 | finance.yahoo.comAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year ResultsMarch 23, 2024 | seekingalpha.comTELA Bio, Inc. (TELA) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | finance.yahoo.comTELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)March 22, 2024 | stockhouse.comTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryMarch 22, 2024 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)JMP Securities reaffirmed a "market outperform" rating and issued a $15.00 target price on shares of TELA Bio in a research report on Friday.March 22, 2024 | marketbeat.comPiper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00Piper Sandler reduced their price target on TELA Bio from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday.March 22, 2024 | finance.yahoo.comQ4 2023 TELA Bio Inc Earnings CallMarch 21, 2024 | benzinga.comRecap: TELA Bio Q4 EarningsMarch 21, 2024 | msn.comTELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023March 21, 2024 | finance.yahoo.comTELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023March 21, 2024 | markets.businessinsider.comStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA BioMarch 21, 2024 | finance.yahoo.comTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsMarch 21, 2024 | globenewswire.comTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsMarch 21, 2024 | markets.businessinsider.comTela Bio Announces Commercial Launch Of Liquifix Devices In U.S.March 21, 2024 | globenewswire.comTELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryMarch 20, 2024 | marketwatch.comTELA Bio Sells Distribution Rights to Wound-Care Product to MimedxMarch 20, 2024 | markets.businessinsider.comTELA Bio is about to announce its earnings — here's what to expectMarch 20, 2024 | globenewswire.comTELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDXMarch 7, 2024 | finance.yahoo.comTELA Jul 2024 10.000 callMarch 7, 2024 | finance.yahoo.comTELA Jul 2024 7.500 putFebruary 29, 2024 | globenewswire.comTELA Bio to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | msn.comTELA Bio Awards Restricted Stock Units to New Hires in Bid to Attract Top TalentFebruary 23, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Get TELA Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW TELA Media Mentions By Week TELA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TELA News Sentiment▼1.370.86▲Average Medical News Sentiment TELA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TELA Articles This Week▼31▲TELA Articles Average Week Get TELA Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Apyx Medical News Today iCAD News Today Co-Diagnostics News Today T2 Biosystems News Today PolyPid News Today SI-BONE News Today Orthofix Medical News Today Bioventus News Today Iradimed News Today Surmodics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TELA) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
